Ertapenem for Diabetic Foot Infections

Antimicrobial Coverage

• Ertapenem provides once-daily dosing with relatively broad-spectrum coverage that includes anaerobic organisms, making it convenient for treatment 1
• Ertapenem has suboptimal activity against Staphylococcus aureus and is not active against Pseudomonas aeruginosa 1, 2

Clinical Application

• Ertapenem (1g IV once daily) is recommended for moderate to severe diabetic foot infections, particularly when there is low suspicion of Pseudomonas aeruginosa 1, 2
• Current guidelines suggest that ertapenem can be considered as part of group 1 carbapenems for moderate to severe diabetic foot infections, especially when there is a history of recent antibiotic exposure 2, 3

Limitations and Considerations

• Tigecycline has been found to be significantly inferior to ertapenem in clinical outcomes and has a higher rate of adverse effects, so ertapenem is preferred between these options 5

Treatment Algorithm

• For moderate to severe diabetic foot infections requiring parenteral therapy, use ertapenem 1g IV once daily when Pseudomonas aeruginosa is not suspected 1, 2
• Obtain proper wound cultures before initiating antibiotics to guide definitive therapy 4
• Combine antibiotic therapy with appropriate surgical debridement and wound care for optimal outcomes 4